Clinical trial

ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.

NCT07390409

StatusNOT_YET_RECRUITING

Study typeOBSERVATIONAL

Start date2026-01-29

PhaseN/A

Study timeline

Study start (estimated)2026-01-29Date precision: day

Registry last updated2026-02-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIVunresolved

Interventions

Lenacapavir InjectionDRUG · verified · RxNorm: lenacapavir Injection

Cabotegravir (CAB) LADRUG

Tenofovi-Emtricitabine (TDF/FTC) tabletDRUG

Sponsors & collaborators

Desmond Tutu HIV Foundationlead sponsor

Bill and Melinda Gates Foundationcollaborator

Gilead Sciencescollaborator

ViiV Healthcarecollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07390409 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.